Watertown, Massachusetts
Delaware
Founded in Australia, pSivida was incorporated in the U.S. in June 2008
June 30th
EyePoint Pharmaceuticals stock is traded on the NASDAQ (PSDV), Australian (PVA), and Frankfurt (PV3) exchanges
We have license agreements with Bausch and Lomb for both the Vitrasert™ product and the Retisert® product. We also have a license agreement with Alimera for ocular applications of the ILUVIEN® device. We have a collaboration agreement with Pfizer for the Durasert device delivering latanoprost.
We have 2 FDA approved products, Vitrasert and Retisert. Both are being sold by Bausch and Lomb. ILUVIEN received a positive outcome from the EU Decentralized Procedure and has subsequently received formal marketing authorization in the U.K., Austria, France, Germany, Portugal, Spain,Italy, Norway and Denmark.
Computershare Investor Services
Stern Investor Relations
212-362-1200
eyepoint@sternir.com
Contact:
Computershare Investor Services
P.O. Box 43078
Providence, RI 02940
United States of America
Phone: 781-575-2879
Fax: 781-575-3605
No
Deloitte & Touche, LLP
Ropes & Gray, LLP